The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .
A double-blind study to compare the efficacy, tolerance and safety of two doses of the angiotensin converting enzyme inhibitor ramipril with placebo.
In a r and omized , double-blind trial , 2 doses of ramipril ( 2.5 and 5 mg once daily ) were compared with placebo in patients with mild to moderate essential hypertension . A 2-week placebo run-in phase was followed by 4 weeks of treatment . Eighty-six patients entered the study and 17 withdrew during the course of the study . Both doses of ramipril appeared to be more effective than placebo in reducing blood pressure , but significant differences between 2.5 mg of ramipril and placebo were not found in any statistical analyses . In the endpoint analyses ( taking the last measurement from each patient ) , the patients receiving 5 mg of ramipril had significantly larger decreases in blood pressure than the patients receiving placebo ( t tests : st and ing systolic , p less than 0.001 ; supine diastolic , p less than 0.05 ; st and ing diastolic , p less than 0.05 ) and also than the patients receiving 2.5 mg of ramipril ( st and ing systolic , p less than 0.05 ) . It appears from the results of this study that the minimum effective dosage of ramipril is 5 mg once daily . No clinical ly relevant side effects or clinical ly relevant changes in laboratory values were observed
The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .